Back

Impact of SGLT2-inhibitors on cardiac function and structural changes in patients with heart failure and reduced ejection fraction - Results from the REWIN-HFrEF Study

1 September 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Novel insights into heart failure therapy Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Maria Grazia De Angelis

Spedali Civili, University Of Brescia, Brescia (Italy)

5 More presentations in this session

Presentation thumbnail
Hemodynamic effect of angiotensin-neprilysin inhibition in diastolic dysfunction after acute myocardial infarction
Mr P. Hartmund Frederiksen (Odense, DK)
Abstract Slides Video
Presentation thumbnail
The rhythm control strategy in patients with atrial fibrillation and heart failure with preserved or reduced ejection fraction: the single centre experience
Doctor M. Pandrc (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes for patients with severe HFrEF diagnosed and treated in a community setting with the 'four pillars' of pharmacotherapy
Doctor R. Bain (Grimsby, GB)
Abstract Slides Video
Presentation thumbnail
Integrating cardio-oncology in Multiple Myeloma: risk stratification and management of therapy-related cardiovascular toxicity
Doctor D. Faro (Catania, IT)
Abstract Slides Video
Presentation thumbnail
A study to assess the role of vericiguat in the cardio-pulmonary pathophysiology in worsening heart failure with reduced ejection fraction (REVOLUT- HFrEF): preliminary results at 3 months follow up
Doctor S. Prosperi (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Novel insights into heart failure therapy

The Event

Event poster

ESC Congress 2025

1 September 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
DISCOVER SGLT2i - myocardial deformation and reverse remodelling after SGLT2 inhibitors
thumbnail
Congress Presentation
Effect of sodium-glucose type 2 cotransporter inhibitors on cardiac structure and function in patients with normal ejection fraction
thumbnail
Congress Presentation
The impact of sodium glucose transporter 2 inhibitors on cardiac remodeling in a large cohort of unselected patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources